Synthesis, anticancer evaluation, molecular docking and ADME study of novel pyrido[4ʹ,3ʹ:3,4]pyrazolo[1,5-a]pyrimidines as potential tropomyosin receptor kinase A (TrKA) inhibitors

Table 3 The IC₅₀ values (the drug concentrations that inhibited 50% of cell proliferation) of the compounds on HCT-116 cell line

HCT116	20 µg/l	10 µg/l	5 µg/l	IC₅₀/µg/l
Doxo	95.26	77.18	62.14	3.641
1	71.08	52.09	16.23	10.81
4a	84.77	71.78	56.23	3.966
4b	66.23	21.33	7.31	15.73
7a	91.78	84.52	50.82	4.866
7b	91.94	70.12	67.87	2.487
7c	68.85	68.21	50.56	4.072
7k	62.92	46.55	39.48	10.25
7l	91.59	61.58	57.14	4.457
9a	65.98	55.47	34.38	9.109
9b	59.80	40.50	22.09	14.15
9c	89.80	67.13	59.74	3.778
14a	58.72	55.79	28.84	10.99
15b	84.20	66.87	26.10	7.754
16a	87.26	74.90	54.16	4.369
16b	85.28	52.73	23.18	9.174
16c	99.23	78.34	55.98	4.503

ISSN: 2661-801X